CTOs on the Move

Neuron23

www.neuron23.com

 
Neuron23™ Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.neuron23.com
  • 681 Gateway Blvd 3rd Floor
    South San Francisco, CA USA 94080
  • Phone: 310.403.8951

Executives

Name Title Contact Details

Funding

Neuron23 raised $80M on 12/16/2020

Similar Companies

Abengoa Bioenergy Corporation

Abengoa Bioenergy Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Ichnos

Start-up spirit. Experienced leadership. A mission of change. Ichnos (`īk-nōz) Sciences—a name taken from an ancient Greek word for “footprint”—is shifting how the world thinks about innovation in medicine. With a new approach to the research, discovery, and development of breakthrough therapies in oncology, we`re forging a new path forward. We aim to treat disease holistically, seeking to provide curative therapies that extend human life and improve quality of life. Science SHIFTED…from now on. Headquartered in the NYC metro area with additional teams in Switzerland, ours is a mission rooted in purpose and aimed at progress. Ichnos Sciences is fast-paced, forward-looking and visionary—a company where science, creativity, and a diversity of ideas thrive. We move quickly and nimbly, working together, challenging and supporting one another and ourselves to go further, look deeper, take scientific risks, shift perspectives, and drive forward the scientific advances that will leave an imprint on the world around us. At Ichnos Sciences, we dare to imagine a world where cure is possible. And we invite you to join us. Because cure is possible.

Immunitas Therapeutics

Immunitas Therapeutics is a single cell genomics-based drug discovery company.

Intellikine

Intellikine is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Renalytix

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.